Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Takeda Oncology.

Oncology Consultations®: Expanding Options for Transplant-Eligible Patients With ALL: Putting Novel Therapies into Context for Ph+ Disease

Release Date: October 8, 2020
Expiration Date: October 8, 2020

Activity Overview

Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy that can manifest at any age. The current treatment strategy is complex because it is determined primarily by the Philadelphia chromosome status and patient age, and lacks a defined standard of care. While dramatic advances have been made over the past three decades, with overall 5-year relative survival rate increasing from 41% to 70%, the treatment of relapsed or refractory ALL remains challenging. Progress is being made in terms of increased understanding of disease pathophysiology as related to identification of new cytogenetic and molecular abnormalities, as well as development of novel targeted agents for the treatment of ALL. The addition of tyrosine kinase inhibitors, monoclonal antibodies and novel immune therapies to the treatment landscape has improved clinical outcomes. These developments have shifted clinical management from a “one-size-fits-all” approach to a more individualized treatment approach based on immunophenotypic, cytogenetic, and molecular features.
This Oncology Consultations® program provides an in-depth update of the pathophysiology and management of patients with Philadelphia chromosome positive (Ph+) ALL.  The expert faculty will provide an engaging online program that is ideal for hematologist/oncologists and medical oncologists who treat ALL and focuses on a comprehensive review of novel and emerging therapies for the management of  Ph+ ALL, putting recent trial data into clinical practice, and providing insight into the future of Ph+ ALL Management.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

These activities are intended for hematologist/oncologists and medical oncologists who treat ALL. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with ALL are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Outline novel strategies to stratify risk among patients with ALL
  • Detail how novel targeted therapies have impacted decision-making concerning transplant in ALL treatment settings
  • Apply recent evidence concerning approaches for the management of ALL in the context of how these data relate to transplant settings
  • Discuss methods to proactively mitigate and manage treatment-related toxicities among patients with ALL who are managed in transplant setting

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Elias Jabbour, MD
Elias Jabbour, MD
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Amgen, AbbVie, Spectrum, Bristol Myers Squibb, Takeda, Pfizer, Adaptive Biotechnologies.

James M. Spencer, MD, MS
Hagop M. Kantarjian, MD
Professor of Clinical Dermatology
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Hagop M. Kantarjian, MD has no relevant financial relationships with commercial interest.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By